#CANF

1 week ago

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced the

#CANF Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

www.stocktitan.net/news/CANF/can-fite-annou...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

1 week ago

📢 Stocks Trending NOW: #MOBX #MSTR #ANF #ASNS #CRWD #MRNA #CANF #KMB #NOW #WIX

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study Can-Fite (NYSE American: CANF) reported that its Phase 2a open-label study of namodenoson in advanced pancreatic ductal adenocarcinoma met its primary endpoint of safety. The trial enrolled 20 heavily pretreated patients; namodenoson was very well tolerated with no new safety signals identified.Survival follow-up is ongoing; one-third of patients were alive at data cut-off. Namodenoson holds FDA Orphan Drug Designation for pancreatic cancer and remains under further clinical evaluation.

#CANF Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

www.stocktitan.net/news/CANF/can-fite-s-nam...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

2 months ago

📢 Stocks Trending NOW: #NVDA #SIDU #MU #SNDK #TSLA #CANF #ORCL #DTCK #ASPC #AVGO

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

2 months ago

PRISM Morning Movers
Premarket Gainers:
Davis Commodities Limited. ( #DTCK) up 97%
Can-Fite BioPharma Ltd. ( #CANF) up 48%
A Space III Acquisition Corp. ( #ASPC) up 43%
Sidus Space, Inc. ( #SIDU) up 33%
Premarket Decliners:
Aptevo Therapeutics Inc. ( #APVO) dawn -21%
Pearson plc ( #PSO) down -13%

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction Can-Fite (NYSE American: CANF) announced that the Brazilian Patent Office granted Patent No. BR112015002697-4 for “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction” on Dec. 26, 2025.The patent provides intellectual‑property protection in Brazil for Can‑Fite’s A3AR agonists for sexual dysfunction, complements the company’s global patent portfolio, and may support future partnering or commercialization opportunities in Latin America. Can‑Fite cites preclinical and clinical data suggesting A3AR activation may modulate signaling related to erectile and sexual function.

#CANF Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

www.stocktitan.net/news/CANF/can-fite-grant...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change Can-Fite (NYSE American: CANF) announced a 1-for-3,000 reverse split of ordinary shares following shareholder approval on November 10, 2025.The split will be recorded on the Tel-Aviv Stock Exchange on January 2, 2026, with first TASE trading of consolidated shares on January 5, 2026. Concurrently the ADS ratio will change from 1 ADS = 300 ordinary shares to 1 ADS = 2 ordinary shares, effective on the NYSE American on January 5, 2026, requiring an exchange of every 20 ADS for 1 new ADS.The company will reduce authorized ordinary shares from 42,000,000,000 to 14,000,000 and issue no fractional ordinary shares (rounded up); ADS fractional entitlements will be aggregated and sold by the depositary bank. New CUSIP: 13471N409.

#CANF Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

www.stocktitan.net/news/CANF/can-fite-annou...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Can-Fite Provides Update on Clinical and Financial Status Can-Fite BioPharma (NYSE American: CANF) provided a clinical and financial update on Dec 16, 2025. Key clinical programs: Namodenoson is enrolling a pivotal Phase III in advanced hepatocellular carcinoma (Child-Pugh B7) with an interim analysis ~Q4 2026, a Phase IIb in MASH (following positive Phase IIa published data), and a Phase IIa in pancreatic cancer with data expected Q2 2026. Piclidenoson is enrolling a pivotal Phase III in psoriasis with an interim readout ~Q2 2026. Financials: cash and short-term deposits were $6.45M as of June 30, 2025; the company raised $5M in a July 28, 2025 public offering and $2.2M via ATM in Nov 2025.

#CANF Can-Fite Provides Update on Clinical and Financial Status

www.stocktitan.net/news/CANF/can-fite-provi...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference Can-Fite BioPharma (NYSE American: CANF) announced that CEO Motti Farbstein will present at NobleCon21 on Wednesday, December 3, 2025 at 12:30 PM ET in Boca Raton, Florida.The presentation will cover the company's advanced-stage drug development pipeline, including listed trials: Phase III liver cancer, Phase IIa pancreatic cancer, Phase III psoriasis, Phase IIb MASH, and an upcoming Phase II in Lowe syndrome. The CEO will also hold 1x1 investor meetings.Can-Fite noted existing out-licensing and global distribution agreements worth up to $130 million for pharma indications and up to $325 million for veterinary indications. A high-definition webcast will be available the following day and archived for 90 days on Can-Fite, NobleCon, and Channelchek websites.

#CANF Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

www.stocktitan.net/news/CANF/can-fite-s-lat...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach $3.1 billion by 2030 Piclidenoson is currently in development for the treatment of osteoarthritis in pets; Clinical studies show efficacy in dogs, representing a $3 billion market RAMAT

#CANF Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference

www.stocktitan.net/news/CANF/can-fite-to-ad...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil Can-Fite (NYSE:CANF) received a Notice of Allowance in Brazil for a patent titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction,” extending IP protection for its CF602 erectile dysfunction candidate beyond previously granted U.S. and European patents.The release highlights a $3.2 billion ED market, where 30%–35% of patients are non-responders to PDE5 inhibitors and an estimated 16 million U.S. men with diabetes may be contraindicated for those drugs. Preclinical results in a diabetic rat model reported a single-dose full erectile recovery, increased arterial blood flow, and dose-dependent improvements in intracavernosal pressure, smooth muscle/collagen ratio, VEGF, and eNOS.

#CANF Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

www.stocktitan.net/news/CANF/can-fite-s-cf6...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #HD #OLMA #BIDU #NET #MDT #CANF #PACS #PDD #KLAR #COIN

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson Can-Fite (NYSE American: CANF) reported that a patient with advanced hepatocellular carcinoma treated with Namodenoson reached 9 years overall survival with a complete response and remains cancer-free while on compassionate use treatment.The company is enrolling a pivotal Phase III HCC study in Israel, Europe and the U.S.; the protocol was agreed with the FDA and EMA. Namodenoson holds Orphan Drug status from both agencies and Fast Track status from the FDA. A compassionate use program is active in Israel and Romania.

#CANF Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson

www.stocktitan.net/news/CANF/can-fite-9-yea...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update Can-Fite BioPharma (NYSE American: CANF) reported H1 2025 financial results and clinical updates. The company reached significant milestones in its drug development programs, with Namodenoson achieving over 50% enrollment in its Phase 2a pancreatic cancer trial and receiving FDA compassionate use approval. A breakthrough UCLA study demonstrated Piclidenoson's potential for treating vascular dementia, targeting a $6 billion market.Financial results showed revenues of $0.20 million, down 36.07% year-over-year. Net loss increased to $4.87 million from $3.95 million in H1 2024. The company held $6.45 million in cash and equivalents as of June 30, 2025, and completed a $5 million public offering in July 2025.

#CANF Can-Fite Reports H1 2025 Financial Results and Clinical Update

www.stocktitan.net/news/CANF/can-fite-repor...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough Phase 2a Pancreatic Cancer Drug Shows Promise as Trial Reaches Major Milestone FDA-designated orphan drug demonstrates favorable safety profile in advanced pancreatic cancer trial. Key enrollment milestone reached. Learn more about this potential treatment.

#CANF Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone

www.stocktitan.net/news/CANF/pancreatic-can...

1 0 0 0

StockTitan

@stocktitan.net

7 months ago

Can-Fite Announces Up To $15.0 Million Public Offering Can-Fite BioPharma (NYSE American: CANF) has announced a public offering to raise up to $15.0 million in gross proceeds. The offering includes 8,333,333 American Depositary Shares (ADSs) at $0.60 per ADS, along with short-term warrants to purchase up to 16,666,666 ADSs.The initial gross proceeds are expected to be $5.0 million, with potential additional proceeds of $10.0 million if all warrants are exercised. The warrants have an exercise price of $0.60 per ADS and will expire in 24 months. The offering is expected to close around July 29, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent.

#CANF Can-Fite Announces Up To $15.0 Million Public Offering

www.stocktitan.net/news/CANF/can-fite-annou...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia Can-Fite BioPharma (NYSE American: CANF) announced breakthrough results from a UCLA study demonstrating the efficacy of Piclidenoson in treating vascular dementia. The study, led by Dr. S. Thomas Carmichael at UCLA's Geffen School of Medicine, showed that Piclidenoson successfully restored tissue integrity and behavioral function in a vascular dementia mouse model.Vascular dementia, the second most common form of dementia after Alzheimer's, currently has no FDA-approved treatments. The global market for vascular dementia treatments is valued at $6 billion as of 2025, with a projected 5% CAGR through 2035. Piclidenoson, a selective A3 adenosine receptor agonist, has already demonstrated a strong safety profile in hundreds of psoriasis patients through Phase 2 and Phase 3 clinical studies.

#CANF Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia

www.stocktitan.net/news/CANF/breakthrough-s...

0 0 0 0

OpheliaPG

@opheliapg.bsky.social

9 months ago

Rubio, Cuba & the Zionist Model Lawrence Davidson on how the history of the Cuban American lobby, in copying the Israel lobby, has prepared the U.S. secretary of state to carry out Trump’s often unconstitutional and inhumane bidding...

Rubio, Cuba & the Zionist Model

“we realized pretty soon that to influence the U.S. political system we must copy … the Jewish model and we became very closely allied with the Jewish lobby … in Washington.” #CANF #AIPAC consortiumnews.com/2025/05/26/r...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

FDA Grants Pancreatic Cancer Drug Approval as Major U.S. Medical Centers Rush to Secure Treatment Access Leading U.S. hospitals pursue FDA authorization for Namodenoson after first compassionate use approval in pancreatic carcinoma. See trial updates.

#CANF Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

www.stocktitan.net/news/CANF/following-fda-...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares Can-Fite BioPharma (NYSE American: CANF) has announced a $3.0 million registered direct offering of American Depositary Shares (ADSs). The company will sell 2,500,000 ADSs at $1.20 per share, with the offering expected to close around April 15, 2025.H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering, which is being conducted under a previously filed shelf registration statement. The net proceeds will be allocated to:Research and development fundingClinical trialsWorking capitalGeneral corporate purposes

#CANF Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

www.stocktitan.net/news/CANF/can-fite-annou...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Can-Fite's Massive $685M Partnership Revenue Forecast: 4 Major Disease Treatments in Pipeline New analysis reveals Can-Fite's partnerships could yield $685M through 2029, spanning treatments for psoriasis, liver cancer, and MASH. See full revenue breakdown.

#CANF Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

www.stocktitan.net/news/CANF/can-fite-to-ge...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Can-Fite Reports 2024 Financial Results and Clinical Update Can-Fite BioPharma (NYSE: CANF) reported financial results for 2024 and provided clinical updates. A notable highlight includes an 8-year cancer-free survival in a liver cancer patient treated with Namodenoson under compassionate use. The company's drug candidates showed significant progress:Key Developments:Namodenoson received FDA Orphan Drug Designation for pancreatic cancerPiclidenoson initiated Phase 3 psoriasis trialsPartnership with Vetbiolix for canine osteoarthritis could generate $325 million over next decadeFinancial Results:2024 revenues: $0.67M (down 9.3% YoY)R&D expenses: $5.75M (down 3.8%)Net loss: $7.88M (vs $7.63M in 2023)Cash position: $7.88M as of December 31, 2024

#CANF Can-Fite Reports 2024 Financial Results and Clinical Update

www.stocktitan.net/news/CANF/can-fite-repor...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Major Breakthrough: New Oral Psoriasis Drug Enters Final Testing Phase with Dual Regulatory Backing Novel oral psoriasis treatment advances to pivotal Phase 3 trial with unprecedented FDA & EMA protocol approval. Targets $30B market opportunity. Full analysis inside.

#CANF Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

www.stocktitan.net/news/CANF/can-fite-initi...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity Vetbiolix launches advanced trial for Can-Fite's Piclidenoson, a safer oral treatment for canine arthritis, targeting $445M peak sales in growing pet health market.

#CANF Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

www.stocktitan.net/news/CANF/can-fite-partn...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson Can-Fite BioPharma (NYSE American: CANF) has announced the completion of Phase II study design for Piclidenoson in treating Lowe Syndrome, a rare genetic disease. The open study, led by Dr. Franchesca Emma from Bambino Gesù Children's Hospital, will enroll 5 patients treated with 3 mg Piclidenoson twice daily for 12 months.The study aims to evaluate Piclidenoson's efficacy in increasing 99mTc-DMSA renal uptake. This initiative follows successful pre-clinical work by Dr. Antonella De Matteis at the University of Naples Federico II. Can-Fite has partnered with Fondazione Telethon for the clinical development.Lowe Syndrome, occurring mainly in males, affects approximately 1 in 500,000 people and causes vision problems, kidney issues, and brain abnormalities. The condition currently has no available drug treatment, and patients rarely live beyond 40 years. Pre-clinical studies showed Piclidenoson significantly decreased urinary protein loss, making it the only effective compound found among thousands tested.

#CANF Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

www.stocktitan.net/news/CANF/can-fite-to-in...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

FDA Approval Milestone: Can-Fite's Cancer Drug Namodenoson Gets Special Patient Access Can-Fite's Namodenoson advances with FDA compassionate use approval for pancreatic cancer, while Phase III liver cancer trial progresses. Orphan drug status promises market exclusivity.

#CANF Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

www.stocktitan.net/news/CANF/can-fite-fda-a...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can-Fite's Cancer Drug Protects Heart, Liver and Brain While Fighting Tumors - Phase III Underway Unlike conventional chemotherapy, Can-Fite's Namodenoson demonstrates protective effects on multiple organ systems while targeting advanced liver cancer in FDA Fast Track study.

#CANF Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

www.stocktitan.net/news/CANF/can-fite-innov...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Liver Cirrhosis Breakthrough: Patient's Remarkable Recovery Sparks Hope for 10.6M Sufferers Patient shows complete resolution of cirrhosis symptoms after 20-month Namodenoson treatment, targeting $15B market opportunity in liver disease therapy

#CANF Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson

www.stocktitan.net/news/CANF/disappearance-...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can-Fite (CANF) Reveals $130M Milestone Pipeline: Inside Look with CEO & CSO - Register Now Join Can-Fite's leadership on Feb 25 as they unveil their $70B market strategy, recent $20M milestone achievements, and upcoming catalysts in oncology and inflammation.

#CANF Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

www.stocktitan.net/news/CANF/join-can-fite-...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can-Fite Secures US Patent for Novel Obesity Drug Namodenoson Through 2042 Breakthrough oral obesity treatment shows promising 2.3% weight loss in early trials. Patent strengthens Can-Fite's position in $60.5B obesity market with unique mechanism of action.

#CANF US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug

www.stocktitan.net/news/CANF/us-patent-offi...